


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kaisa Health Group Holdings Limited**

**佳兆業健康集團控股有限公司**

*(Formerly known as Mega Medical Technology Limited 美加醫學科技有限公司)*

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 876)**

**PROFIT WARNING**

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group and information currently available to the Board, the Group is expected to record a profit for the six months ended 30 June 2018 of no more than HK\$2 million, comparing to the profit attributable to the owners of the Company for the six months ended 30 June 2017 of approximately HK\$6.9 million and although there is an increase in revenue and gross profit, net profit is reduced mainly due to the increase in administrative expense and research and development expense, together with a decrease in government grants as compared to the same period last year.

The information contained in this announcement is only based on a preliminary review by the Group's management on the preliminary management accounts of the Group and the information currently available, which have not been reviewed or audited by the auditors of the Company, and is subject to possible adjustments following further internal review. Furthermore, given the current meagre profits, any adjustments made may reverse it to losses or enhance it significantly. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Kaisa Health Group Holdings Limited**  
**Luo Jun**  
*Chairman*

Hong Kong, 15 August 2018

*As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Luo Jun (Chairman) and Mr. Wu Tianyu (Chief Executive Officer), one non-executive Director, namely Mr. Xu Hao, and four independent non-executive Directors, namely Dr. Liu Yanwen, Mr. Wang Wansong, Mr. Fok Hei Yu and Dr. Lyu Aiping.*